1Cohn J N. Structural basis for heart failure. Circulation, 1995, 91:2504 - 2507
2Colucci W. Molecular and cellular mechanisms of myocardial failure.Am J Cardiol, 1997, 80:15-25
3Cohn JN, Levine B, Olevari T, et al. Plasma norepinephrine as a guide to prognwsis in patients with congestive heart failure. N Engl J Med, 1984, 311:819-823
4The Digitalis Invesgation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Eng J Med, 1997, 336:525 - 553
5Packer M, Carver J Rodenheffer RJ. Effect of oral milrinon on mortality in severe chronic heart failure. N Engl J Med, 1991, 325:1468- 1475
6Moe GW, Kouleau JL, Charboneau L, et al. Neurobormoral activation in sevre heart failure: Relations to patient death and the effect of treatment with fleseqiunan. AmHeartJ, 2000, 199:587-595
7Leehat P, Packer M, Chalon S, et al. Clinical effects of β- adrenergic blokade in chronic heart failure. Circulation, 1998, 98:1184 -1191
8Packer M, Bristow MR, Cohn JR, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 1996, 334:1349-1355
9The captopril - Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderateheart failure. JAMA, 1988, 259:293-302
10Cohn JN, Johrnson G, Ziesche S, et al. A comparison of enalapril with by dralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med, 1991, 325:303 - 310
